ClinicalTrials.gg
CompletedNCT00492024Updated Nov 26, 2013Results posted

BAY12-8039: 5 Days for Sinusitis vs Placebo

A Phase 3 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Placebo in Sinusitis, sponsored by Bayer. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-26.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 129 studies in Sinusitis with a site in United States — 6 open to participants now, 12 under way, none of them phase 3. Sinusitis · United States.

Enrollment
8th of 103
374 · median 44
Started
2005
with 6 others
Phase 3
12 of 129
none open now
Registered
20th of 129
by date
Lead sponsor
2 of 129
Bayer

Among the 129 studies in Sinusitis with a site in United States, this one is the 8th largest by enrollment of the 103 interventional ones that give a count, is one of 7 that started in 2005, is one of 12 in phase 3, and was the 20th registered.

Sinusitis

256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.

Browse Sinusitis studies →

Open to participants now

6 of the 129 studies in Sinusitis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Sinusitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of acute bacterial sinusitis, therefore in this study Avelox is considered an investigational drug. In this study Avelox will be compared to placebo.

03

Conditions studied

  • Sinusitis

Keywords

  • Respiratory Tract Infection
  • Bacterial Sinusitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all the following criteria at the time of enrollment:

  • Age >/= 18 years
  • Clinical diagnosis of acute bacterial sinusitis with signs and symptoms present for = 7 days but \< 28 days as defined by A), radiographic, and B) clinical criteria, as follows:

    • Radiographic Criteria: The presence of one or more of the following on a radiographic paranasal sinus film (Waters' view): - Evidence of air-fluid levels - Opacification
    • Clinical Criteria: The presence of two major symptoms, or the presence of at least one major and one minor symptom as defined in the list below:

      • Major symptoms: - Purulent anterior or posterior nasal discharge - Unilateral facial pain or malar tenderness
      • Minor symptoms: - Frontal headache - Fever (oral = 38.0°C/100.4°F, tympanic = 38.5°C/101.2°F, axillary = 37.5°C/99.5°F) - Culture material obtained by sinus puncture; the aspirated specimen sent for Gram stain, quantitative culture and susceptibility testing prior to initiation of antimicrobial therapy

Exclusion criteria

Exclusion Criteria:

Subjects with one or more of the following criteria will not be eligible for this study:

  • History of chronic sinusitis defined as greater than four weeks of continuous symptoms (subjects with recurrent acute sinusitis will be included)
  • History of sinus surgery (antral sinus puncture is not considered as a surgery)
  • Any symptoms that suggest the subject's current illness is allergic rhinitis (e.g. repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
  • Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
374 participants (actual)

Study arms

  • Experimental
    Moxifloxacin 400 mg

    Moxifloxacin 400mg once daily for 5 days

    Drug: Moxifloxacin (Avelox, BAY12-8039)

  • Placebo comparator
    Placebo

    Matching placebo for 5 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))

    The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.

    Time frame: At 'Test-of-Cure' (TOC), Day 1-5 after end of treatment

Secondary outcomes

  1. Treatment Day When Patients Reached Symptom Improvement as Measured by Patient Reported Data, Using Last Observation Carried Forward (LOCF) Approach

    The Sino-Nasal Outcome Test (SNOT-16) was used to assess subject-reported time to symptom improvement. Improvement was defined as a decrease of at least 14 units on the test. This difference is the smallest difference that has been identified as beneficial to subjects.

    Time frame: Daily until 'Test-Of-Cure' (Day 1-5 after end of treatment)

  2. Treatment Day When Patients Returned to Normal Activities as Measured by Patient Reported Data, Using LOCF Approach

    The Activity Impairment Assessment (AIA) questionnaire was used to assess activity impairment at baseline and time to return to normal activities. The AIA was administered prior to first dose, every 24 hours during treatment, and at the TOC visit. Improvement in the AIA total score was defined as a decrease of at least 3 units.

    Time frame: Daily until 'Test-Of-Cure' (Day 1-5 after end of treatment)

  3. Percentage of Subjects With Clinical Improvement During Therapy

    A secondary efficacy variable was clinical response (CR) at the During Therapy visit at day 3 or 4 of treatment. CR was rated as improvement, cure, failure, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.

    Time frame: Day 3 of treatment

  4. Percentage of Subjects With Continued Clinical Cure During Long-Term Follow-Up

    A secondary efficacy variable was clinical response (CR) at the Follow-up visit 17-21 days following the start of treatment. CR was rated as continued cure, failure/relapse, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.

    Time frame: Day 12 to 26 after end of treatment

Other outcomes

  1. Percentage of Subjects With Clinical Cure (Per Protocol Population (PP))

    The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.

    Time frame: At 'Test-of-Cure', Day 1-5 after end of treatment

07

Results

Posted Dec 2, 2009
Limitations and caveats
Confounding factors include concomitant medication for symptomatic relief not standardised, TOC visit occured earlier than for other sinusitis studies, response on placebo underestimated and short-term relief provided by the sinus tap.

Participant flow

The study was conducted at 37 investigative centers in the United States from January 2005 to March 2008.

Treatment
Participant flow — Treatment
MilestoneMoxifloxacin 400 mgPlacebo
Started251123
Completed222101
Not completed2922
Withdrew: Adverse event31
Withdrew: Lack of efficacy2120
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject20
Follow up
Participant flow — Follow up
MilestoneMoxifloxacin 400 mgPlacebo
Started222101
Completed22199
Not completed12
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up11

Outcome measures

PrimaryPercentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))

The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.

Time frame:
At 'Test-of-Cure' (TOC), Day 1-5 after end of treatment
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))
Percentage of subjectsMoxifloxacin 400 mgPlacebo
Success (Clinical Cure)78.166.7
Failure19.233.3
Indeterminate2.70
Complete resolution12.311.1
Improvement65.855.6
Statistical analysis
  • Moxifloxacin 400 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.189 (P-value is adjusted for study center; p-value applies to percentage of subjects with success (clinical cure))Adjusted for study center
SecondaryTreatment Day When Patients Reached Symptom Improvement as Measured by Patient Reported Data, Using Last Observation Carried Forward (LOCF) Approach

The Sino-Nasal Outcome Test (SNOT-16) was used to assess subject-reported time to symptom improvement. Improvement was defined as a decrease of at least 14 units on the test. This difference is the smallest difference that has been identified as beneficial to subjects.

Time frame:
Daily until 'Test-Of-Cure' (Day 1-5 after end of treatment)
Reported as:
Number · participants
Treatment Day When Patients Reached Symptom Improvement as Measured by Patient Reported Data, Using Last Observation Carried Forward (LOCF) Approach
participantsMoxifloxacin 400 mgPlacebo
Day 2147
Day 32610
Day 43113
Day 53916
Test-Of-Cure4319
SecondaryTreatment Day When Patients Returned to Normal Activities as Measured by Patient Reported Data, Using LOCF Approach

The Activity Impairment Assessment (AIA) questionnaire was used to assess activity impairment at baseline and time to return to normal activities. The AIA was administered prior to first dose, every 24 hours during treatment, and at the TOC visit. Improvement in the AIA total score was defined as a decrease of at least 3 units.

Time frame:
Daily until 'Test-Of-Cure' (Day 1-5 after end of treatment)
Reported as:
Number · participants
Treatment Day When Patients Returned to Normal Activities as Measured by Patient Reported Data, Using LOCF Approach
participantsMoxifloxacin 400 mgPlacebo
Day 22215
Day 33117
Day 43517
Day 53719
Test-Of-Cure4222
SecondaryPercentage of Subjects With Clinical Improvement During Therapy

A secondary efficacy variable was clinical response (CR) at the During Therapy visit at day 3 or 4 of treatment. CR was rated as improvement, cure, failure, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.

Time frame:
Day 3 of treatment
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Clinical Improvement During Therapy
Percentage of subjectsMoxifloxacin 400 mgPlacebo
Improvement84.973.3
Indeterminate4.14.4
Missing11.022.2
SecondaryPercentage of Subjects With Continued Clinical Cure During Long-Term Follow-Up

A secondary efficacy variable was clinical response (CR) at the Follow-up visit 17-21 days following the start of treatment. CR was rated as continued cure, failure/relapse, or indeterminate. Clinical evaluation was based on the presence and severity (mild, moderate, or severe) of several signs and symptoms of acute sinusitis.

Time frame:
Day 12 to 26 after end of treatment
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Continued Clinical Cure During Long-Term Follow-Up
Percentage of subjectsMoxifloxacin 400 mgPlacebo
Combined Clinical Cure73.957.7
Clinical Failure / Relapse21.940.0
Missing4.12.2
Other pre-specifiedPercentage of Subjects With Clinical Cure (Per Protocol Population (PP))

The primary efficacy variable was clinical response (CR) at the TOC visit, and was rated as improvement, complete resolution, failure, or indeterminate. Clinical cure, ie, success, was defined as complete resolution or improvement in the signs and symptoms such that no further therapy (antimicrobial, steroid, or irrigation) was required.

Time frame:
At 'Test-of-Cure', Day 1-5 after end of treatment
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Clinical Cure (Per Protocol Population (PP))
Percentage of subjectsMoxifloxacin 400 mgPlacebo
Success82.366.7
Failure17.733.3
Indeterminate00
Complete resolution11.39.5
Improvement71.057.1
Statistical analysis
  • Moxifloxacin 400 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.075 (p-value adjusted for study center; p-value applies to percentage of subjects with success (clinical cure))adjusted for study center

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxifloxacin 400 mg—1/251 (0.4%)49/251 (19.5%)
Placebo—1/123 (0.8%)23/123 (18.7%)
Most frequent serious events
Most frequent serious events
EventMoxifloxacin 400 mgPlacebo
HypertensionVascular disorders0/2511/123
PneumoniaInfections and infestations1/2510/123
Most frequent other events
Most frequent other events
EventMoxifloxacin 400 mgPlacebo
Procedural PainInjury, poisoning and procedural complications6/2516/123
NauseaGastrointestinal disorders11/2512/123
HeadacheNervous system disorders11/2514/123
DizzinessNervous system disorders9/2511/123
InsomniaPsychiatric disorders2/2514/123
DiarrhoeaGastrointestinal disorders5/2513/123
VomitingGastrointestinal disorders3/2513/123
Sinus headacheNervous system disorders6/2512/123
EpistaxisRespiratory, thoracic and mediastinal disorders6/2512/123

Baseline characteristics

Age Continuous
Age Continuous(years)Moxifloxacin 400 mgPlaceboTotal
Mean40.1 ± 13.840.3 ± 13.040.2 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Moxifloxacin 400 mgPlaceboTotal
Female16580245
Male8643129
Causative Organisms Isolated from Pretreatment Specimens at Study Entry
Causative Organisms Isolated from Pretreatment Specimens at Study Entry(participants)Moxifloxacin 400 mgPlaceboTotal
Streptococcus pneumoniae321345
Moraxella catarrhalis71219
Haemophilus influenzae281543
Streptococcus pyogenes224
Staphylococcus aureus11516
Non causative pathogene663298
No pathogene growth10945154
Location of infection
Location of infection(participants)Moxifloxacin 400 mgPlaceboTotal
Left8237119
Right9446140
Bilateral7540115
Severity of infection
Severity of infection(participants)Moxifloxacin 400 mgPlaceboTotal
Moderate15372225
Severe9049139
Mild8210
Duration of infection
Duration of infection(days)Moxifloxacin 400 mgPlaceboTotal
Mean13.2 ± 5.412.7 ± 4.713.0 ± 5.1
08

Study locations

51 sites
  • Birmingham, Alabama 35209, United States
  • Northport, Alabama 35476, United States
  • Jonesboro, Arkansas 72401, United States
  • Little Rock, Arkansas 72205, United States
  • Fresno, California 93710, United States
  • Fresno, California 93720, United States
  • Garden Grove, California 92840, United States
  • Orange, California 92868, United States
  • Roseville, California 95678, United States
  • San Diego, California 92106, United States
  • San Luis Obispo, California 93405, United States
  • Colorado Springs, Colorado 80909, United States
  • Bridgeport, Connecticut 06606, United States
  • Dunnellon, Florida 34432, United States
  • Hialeah, Florida 33013, United States
  • North Miami Beach, Florida 33179, United States
  • Pembroke Pines, Florida 33024, United States
  • Plantation, Florida 33324, United States
  • Atlanta, Georgia 30310, United States
  • Warner Robbins, Georgia 31093, United States
  • Warner Robins, Georgia 31088, United States
  • Louisville, Kentucky 40207, United States
  • Detroit, Michigan 48202, United States
  • Livonia, Michigan 48152, United States
  • Portage, Michigan 49024, United States
  • Butte, Montana 59701, United States
  • Elizabeth, New Jersey 07202-3672, United States
  • Lawrenceville, New Jersey 08698, United States
  • Somerville, New Jersey 08876, United States
  • Rochester, New York 14618, United States
  • Charlotte, North Carolina 28210, United States
  • Raleigh, North Carolina 27609, United States
  • Cincinnati, Ohio 45241, United States
  • Dayton, Ohio 45406, United States
  • Eugene, Oregon 97404, United States
  • Levittown, Pennsylvania 19056, United States
  • Norristown, Pennsylvania 19401, United States
  • Palmyra, Pennsylvania 17078, United States
  • Clarksville, Tennessee 37043, United States
  • Austin, Texas 78705, United States
  • College Station, Texas 77845, United States
  • El Paso, Texas 79904, United States
  • Houston, Texas 77074, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84109, United States
  • Salt Lake City, Utah 84121, United States
  • West Jordan, Utah 84084, United States
  • West Jordan, Utah 84088, United States
  • Tappahannock, Virginia 22560, United States
  • Bellingham, Washington 98225, United States
  • Greenfield, Wisconsin 53228, United States
09

References and documents

Publications

  • Hadley JA, Mosges R, Desrosiers M, Haverstock D, van Veenhuyzen D, Herman-Gnjidic Z. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. Laryngoscope. 2010 May;120(5):1057-62. doi: 10.1002/lary.20878. PubMed 20422704 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2007
First posted
Jun 27, 2007
Start
Jan 2005
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Dec 2, 2009
Last update
Nov 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00492024
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 27, 2007
Start date
Jan 2005
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Dec 2, 2009
Last update
Nov 26, 2013

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion